Haemonetics Corporation Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Haemonetics Corporation on January 9, 2026. The report discloses a material acquisition event under Item 8.01 Other Events.
Key Financial Metrics and Transaction Details
The filing details the acquisition of Vivasure Medical Limited, a Galway, Ireland-based developer of percutaneous vessel closure technology. The financial terms of the transaction are as follows:
- Total Consideration: €100 million for all outstanding equity interests.
- Net Cash Consideration: Approximately €52 million, net of prior investments, loans, and customary closing adjustments.
- Contingent Consideration: Up to an additional €85 million based on sales growth and milestone achievement, subject to adjustments for prior investments and loans.
- Financing: The transaction was funded using available cash on hand.
The filing does not provide specific figures for the Company's overall revenue, profit, cash flow, margins, debt, or liquidity positions outside of the transaction financing method.
Material Changes
The primary material change is the expansion of Haemonetics' portfolio through the acquisition of Vivasure Medical Limited. This represents a strategic entry into next-generation vessel closure technology.
Outlook, Risks, and Management Commentary
Management commentary is limited to the announcement of the acquisition. The contingent consideration structure introduces performance risk, as the additional €85 million is dependent on future sales growth and the achievement of specific milestones. The filing notes that the press release is furnished as an exhibit but is not deemed "filed" for liability purposes under Section 18 of the Exchange Act.
Key Facts for Investor Verification
- Verify the exact net cash outflow of approximately €52 million against the Company's most recent quarterly cash balance.
- Review the specific sales growth targets and milestones required to trigger the up to €85 million in contingent payments.
- Assess the impact of the acquisition on future earnings per share and integration costs, which are not detailed in this 8-K.
- Confirm the status of prior investments and loans made to Vivasure that were netted against the purchase price.